

# Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons

Vera Gielen, MSc,<sup>a,b,c</sup> Annemarie Sykes, MD,<sup>a,b,c,d</sup> Jie Zhu, PhD,<sup>a,b,c</sup> Brian Chan, BSc,<sup>a</sup> Jonathan Macintyre, MD,<sup>a,b,c,d</sup> Nicolas Regamey, MD,<sup>e</sup> Elisabeth Kieninger, MD,<sup>e</sup> Atul Gupta, MD, PhD,<sup>b,f</sup> Amelia Shoemark, PhD,<sup>b,f</sup> Cara Bossley, MD,<sup>b,f</sup> Jane Davies, MD, PhD,<sup>b,f</sup> Sejal Saglani, MD, PhD,<sup>b,f</sup> Patrick Walker, PhD,<sup>g</sup> Sandra E. Nicholson, PhD,<sup>h,i</sup> Alexander H. Dalpke, MD, PhD,<sup>g</sup> Onn-Min Kon, MD, PhD,<sup>d</sup> Andrew Bush, MD, PhD,<sup>b,f</sup> Sebastian L. Johnston, MD, PhD,<sup>a,b,c,d,\*</sup> and Michael R. Edwards, PhD<sup>a,b,c,\*</sup> London, United Kingdom, Bern, Switzerland, Heidelberg, Germany, and Parkville, Australia

**Background:** Rhinovirus infections are the dominant cause of asthma exacerbations, and deficient virus induction of IFN- $\alpha/\beta/\lambda$  in asthmatic patients is important in asthma exacerbation pathogenesis. Mechanisms causing this interferon deficiency in asthmatic patients are unknown.

**Objective:** We sought to investigate the expression of suppressor of cytokine signaling (SOCS) 1 in tissues from asthmatic patients and its possible role in impaired virus-induced interferon induction in these patients.

**Methods:** We assessed *SOCS1* mRNA and protein levels *in vitro*, bronchial biopsy specimens, and mice. The role of *SOCS1* was inferred by proof-of-concept studies using overexpression with reporter genes and *SOCS1*-deficient mice. A nuclear role of *SOCS1* was shown by using bronchial biopsy staining, overexpression of mutant *SOCS1* constructs, and confocal microscopy. *SOCS1* levels were also correlated with asthma-related clinical outcomes.

**Results:** We report induction of *SOCS1* in bronchial epithelial cells (BECs) by asthma exacerbation-related cytokines and by rhinovirus infection *in vitro*. We found that *SOCS1* was increased *in vivo* in bronchial epithelium and related to asthma severity. *SOCS1* expression was also increased in primary BECs from asthmatic patients *ex vivo* and was related to interferon

deficiency and increased viral replication. In primary human epithelium, mouse lung macrophages, and *SOCS1*-deficient mice, *SOCS1* suppressed rhinovirus induction of interferons.

Suppression of virus-induced interferon levels was dependent on *SOCS1* nuclear translocation but independent of proteasomal degradation of transcription factors. Nuclear *SOCS1* levels were also increased in BECs from asthmatic patients.

**Conclusion:** We describe a novel mechanism explaining interferon deficiency in asthmatic patients through a novel nuclear function of *SOCS1* and identify *SOCS1* as an important therapeutic target for asthma exacerbations. (*J Allergy Clin Immunol* 2015;■■■■:■■■-■■■.)

**Key words:** Rhinovirus, asthma, asthma exacerbation, atopy, interferon, innate immunity, cytokine,  $T_H2$  inflammation, suppressor of cytokine signaling

Asthma exacerbations are the major cause of morbidity, mortality, and health care costs in asthmatic patients and cause a decrease in lung function.<sup>1</sup> Respiratory tract virus infections, of which human rhinoviruses are by far the most common,<sup>2,3</sup> cause

From <sup>a</sup>the Airway Disease Infection Section and <sup>f</sup>Respiratory Pediatrics, National Heart and Lung Institute, and <sup>c</sup>the Centre for Respiratory Infection, Imperial College London; <sup>b</sup>MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London; <sup>d</sup>Imperial College Healthcare National Health Service Trust, London; <sup>e</sup>Pediatric Medicine, University of Bern; <sup>g</sup>the Department of Infectious Diseases, Medical Microbiology and Hygiene, University of Heidelberg; <sup>h</sup>the Walter & Eliza Hall Institute, Parkville; and <sup>i</sup>the Department of Medical Biology of the University of Melbourne, Parkville.

\*These authors contributed equally to this work.

V.G. was funded by a studentship from the National Heart Lung Institute Foundation, Imperial College London. M.R.E. was supported by a Fellowship and S.L.J. was supported by a Chair from Asthma UK (RF07\_04, CH11SJ respectively). A.S. was funded by a MRC Clinical Research Fellowship. This work was supported in part by grants from the British Lung Foundation (P06/13), MRC project grant G0601236, MRC Centre grant G1000758, ERC FP7 Advanced grant 233015 (to SLJ), the National Institute of Health Research Biomedical Research Centre funding scheme, National Institute of Health Research BRC Project grant P26095, Predicta FP7 Collaborative Project grant 260895, and the Wellcome Trust-sponsored Centre for Respiratory Infection (CRI). A.B. was supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. P.W. was supported by the German Research Foundation grants Da592/4 and SFB938. S.E.N. was supported by National Health and Medical Research Council Program grants 461219 and 1016647.

Disclosure of potential conflict of interest: V. Gielen has received research support from the National Heart and Lung Institute. A. Sykes has received research support from the Academy of Medical Sciences—Clinical Lecturer starter grant and MRC Clinical

Training Fellowship. J. Davies has consultant arrangements with Vertex Pharmaceuticals, Novartis, PTC, and Bayer; has provided an EMA review of Vertex investigation plans; has received payment for lectures from Vertex, Forest, Novartis, and Bayer; and has received payment for development of educational presentations from Vertex and the European Cystic Fibrosis Society. S. E. Nicholson has received research support from the National Health and Medical Research Council, Australia. A. H. Dalpke has received research support from the German Research Foundation (DFG, Da592/4, SFB938) and Gilead. O.-M. Kon has received research support from a Boehringer Ingelheim ERS 2014 travel grant. S. L. Johnston has received research support and consultant fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, and Novartis; has received research support and consultant fees from and is a shareholder in Synairgen; has received consultant fees from Grunenthal and Bioforce; and has UK, international, European, Japanese, Hong Kong, and US patents. M. R. Edwards has received research support from the Asthma UK Fellowship (RF07\_04), the Medical Research Council (G0601236), and the British Lung Foundation (P06/13). B. Chan did not return a conflict of interest disclosure statement. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication April 27, 2014; revised October 27, 2014; accepted for publication November 12, 2014.

Corresponding author: Michael R. Edwards, PhD, Airway Disease Infection Section, National Heart and Lung Institute, St Mary's Campus, Imperial College London, London W2 1PG, United Kingdom. E-mail: michael.edwards@imperial.ac.uk. 0091-6749

Crown Copyright © 2014 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

<http://dx.doi.org/10.1016/j.jaci.2014.11.039>

**Abbreviations used**

|                 |  |
|-----------------|--|
| AA:             | Atopic asthma                                    |
| BAL:            | Bronchoalveolar lavage                           |
| BEC:            | Bronchial epithelial cell                        |
| CISH:           | Cytokine-inducible SH2-containing protein        |
| GFP:            | Green fluorescent protein                        |
| ISG:            | Interferon-stimulated gene                       |
| ISRE:           | Interferon-stimulated response element           |
| KC:             | Keratinocyte-derived chemokine                   |
| LIX:            | LPS-induced CXC chemokine                        |
| NANA:           | Nonatopic nonasthmatic                           |
| NF- $\kappa$ B: | Nuclear factor $\kappa$ B                        |
| NLS:            | Nuclear localization sequence                    |
| polyI:C:        | Polyinosinic-polycytidylic acid                  |
| SOCS:           | Suppressor of cytokine signaling                 |
| SOCS1 wt:       | Full-length wild-type human SOCS1                |
| STAT:           | Signal transducer and activator of transcription |
| STRA:           | Severe therapy-resistant atopic asthma           |

the great majority of asthma exacerbations. The mechanisms involved in asthma exacerbations are poorly understood, but increased susceptibility to rhinovirus infections is strongly implicated.<sup>4,5</sup>

We originally reported impaired induction of the innate antiviral IFN- $\beta$ <sup>6</sup> and IFN- $\lambda$ <sup>7</sup> by rhinovirus infection in lung cells from asthmatic patients and implicated deficiency of IFN- $\lambda$  in asthma exacerbation severity in human subjects *in vivo*.<sup>7</sup> Recent studies have confirmed deficient respiratory tract virus induction of IFN- $\alpha$ , IFN- $\beta$ , and/or IFN- $\lambda$  in bronchial epithelial cells (BECs), bronchoalveolar lavage (BAL) macrophages, peripheral blood dendritic cells, and PBMCs from asthmatic patients.<sup>8-14</sup> Although impaired interferon induction might be associated with asthma control,<sup>15</sup> the mechanism or mechanisms responsible for impaired interferon induction are currently unknown. Two recent studies reported that exogenous TGF- $\beta$  enhanced rhinovirus replication in fibroblasts and BECs and that this was accompanied by reduced interferon levels.<sup>16,17</sup> The latter study also reported that anti-TGF- $\beta$  treatment of BECs from asthmatic patients was accompanied by reduced suppressor of cytokine signaling (*SOCS*) 1 and *SOCS3* gene expression,<sup>17</sup> possibly associating these SOCS proteins with interferon deficiency, but no investigations of SOCS function were performed.

There are 7 SOCS family members in human subjects and mice: SOCS1 through SOCS6 and cytokine-inducible SH2-containing protein (CISH). The family is characterized by a central SH2 domain and a C-terminal SOCS box motif that couples SOCS proteins to a Cullin-RING E3 ubiquitin ligase complex. Therefore SOCS proteins can act as adaptors to target bound proteins for ubiquitination and proteasomal degradation and thus function as negative regulators of cytokine signaling. SOCS1 through SOCS3 have been studied in detail, including development of knockout mice.<sup>18-20</sup> *SOCS1* deletion causes fatal inflammation, which can be rescued by deletion of *IFNG*.<sup>18</sup> In mice SOCS1 and SOCS2 negatively regulate T<sub>H</sub>2 immunity<sup>19,21-23</sup>; however, a human polymorphism enhancing SOCS1 expression is associated with asthma.<sup>24</sup> T-cell SOCS3 mRNA levels are increased in asthmatic patients and correlate with IgE levels,<sup>20</sup> but a functional role for SOCS3 in human asthma is unknown, and thus the role of SOCS proteins in asthma is unclear.

In the context of viral infections, SOCS proteins suppress cytokine receptor signaling through inhibition of Janus-activated kinase and signal transducer and activator of transcription (STAT) signaling,<sup>25-27</sup> and preliminary data suggest that SOCS1 and SOCS3 might suppress influenza-induced IFN- $\beta$  promoter activation.<sup>28</sup> However, there are no data on the possible role of SOCS proteins in suppressing viral induction of interferons in patients with asthma and during asthma exacerbations.

We hypothesized that SOCS1/3 would be induced by proinflammatory cytokines and rhinovirus infection in BECs *in vitro*. Thus we investigated SOCS expression in human primary BECs from asthmatic patients *ex vivo* and their possible role in interferon deficiency and increased viral replication in these cells. We also investigated whether SOCS1/3 proteins could directly suppress viral induction of innate interferons in airway cells *in vitro* and *in vivo*. We found that SOCS1, but not SOCS3, levels were increased in cells from asthmatic patients and also found that nuclear localization of SOCS1 was required for suppression of virus-induced interferons. This suppression was independent of the only known nuclear function of SOCS1, which is induction of proteasomal degradation of signaling proteins. Thus we describe a novel mechanism explaining interferon deficiency in asthmatic patients, a new nuclear function of SOCS1, and identify SOCS1 as an important therapeutic target for asthma exacerbations.


**METHODS**

For detailed methods, including patient data, animal models, reagents, experimental protocols, and statistical analysis, please see the [Methods](#) section and [Tables E1-E3](#) in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org).

**RESULTS****SOCS1 is induced in primary BECs by proinflammatory cytokines and rhinovirus**

*SOCS3* mRNA expression is increased in T cells in asthmatic patients,<sup>20</sup> but upregulation of SOCS1 by IL-13 in airway smooth muscle cells from asthmatic patients is impaired.<sup>22</sup> Thus whether SOCS proteins are upregulated in asthmatic patients is uncertain, and whether SOCS proteins are upregulated in cells that are infected by respiratory tract viruses is unknown. Therefore we first investigated the effects of the T<sub>H</sub>2 cytokines IL-4 and IL-13 on *SOCS1* through *SOCS6* and *CISH* mRNA and protein expression in BECs because these cytokines are strongly implicated in asthma pathogenesis.<sup>29,30</sup> IL-4 and IL-13 both induced *SOCS1* mRNA and protein expression ([Fig 1, A](#)). Densitometric analysis for the Western blots in [Fig 1](#) are shown in [Fig E1](#) in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org). No other SOCS proteins/mRNAs were induced by IL-4 or IL-13, with the exception of CISH, which was significantly induced by both.

We next investigated the ability of the proinflammatory cytokines TNF- $\alpha$  and IL-1 $\beta$ , rhinovirus infection, and polyinosinic-polycytidylic acid (polyI:C; as a mimic of other viral infections) to induce SOCS expression in BECs. We found that TNF- $\alpha$  and IL-1 $\beta$  both induced SOCS1 ([Fig 1, B](#)) but not any other SOCS family member, whereas both SOCS1 ([Fig 1, C](#)) and SOCS3 (see [Fig E2](#) in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)) were induced by RV1B (representative of minor group rhinoviruses), RV16 (major group), and polyI:C. RV1B




**FIG 1.** SOCS1 mRNA and protein were induced in primary BECs by viruses and cytokines important in asthma pathogenesis. **A**, The  $T_H2$  cytokines IL-4 and IL-13 both induced SOCS1 mRNA and protein in a time-dependent manner. **B**, The proinflammatory cytokines TNF- $\alpha$  and IL-1 $\beta$  also induced SOCS1 mRNA and protein in a time-dependent manner. **C**, RV1B, RV16, and 1  $\mu$ g/mL polyI:C all induced SOCS1 mRNA and protein in a time-dependent manner. \* $P < .05$  versus medium-treated cells.

and RV16 did not induce SOCS2, SOCS4 through SOCS6, or CISH in BECs. The induction of *SOCS1* by RV1B and RV16 was susceptible to UV irradiation and through filtering out virus with a 30-kDa molecular weight filter and was dose dependent (see Fig E1). These data indicate that SOCS1 is induced by proinflammatory cytokines and rhinovirus infection in primary human BECs.


### SOCS1 protein expression is increased in bronchial epithelium from asthmatic adults

We next investigated the abundance of SOCS1 and SOCS3 proteins in biopsy specimens of adults with uninfected mild-to-moderate atopic asthma (AA) compared with nonatopic nonasthmatic (NANA) adult control donors. SOCS1, but not SOCS3, staining intensity was significantly increased in the





**FIG 3.** SOCS1 suppressed rhinovirus-induced interferon induction but not rhinovirus-induced proinflammatory cytokine induction. **A**, SOCS1-transfected cells showed completely suppressed RV1B-induced IFN- $\beta$  and IFN- $\lambda$ 1 promoter activation versus pORF empty vector control at 24 hours.  $***P < .001$ . **B**, RV1B-induced IFN- $\beta$  mRNA expression was increased in *ex vivo*-cultured BAL macrophages from *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> mice compared with *IFN- $\gamma$* <sup>-/-</sup> mice. No differences were observed between these 2 groups for RV1B-induced TNF- $\alpha$  mRNA.  $*P < .05$ . **C**, RV1B-induced IFN- $\alpha$  expression (8 hours after infection) was significantly increased in RV1B-infected *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> mice compared with *IFN- $\gamma$* <sup>-/-</sup> mice. BAL IFN- $\lambda$  (24 hours) levels showed a nonsignificant trend for increase in RV1B-infected *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> mice, whereas CCL5 levels (24 hours) were also significantly increased in RV1B-infected *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> mice compared with *IFN- $\gamma$* <sup>-/-</sup> mice. CXCL1/KC and LIX/CXCL5 (both 48 hours) were both decreased in BAL fluid from RV1B-infected *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> mice compared with *IFN- $\gamma$* <sup>-/-</sup> mice. A mixture of *SOCS1*<sup>-/-</sup> *IFN- $\gamma$* <sup>-/-</sup> and *IFN- $\gamma$* <sup>-/-</sup> mice was used for the UV-RV1B and UV-RV1B plus IL-13 groups.  $*P < .05$  and  $***P < .001$ . *ns*, Not significant.



**FIG 4.** SOCS1, but not SOCS3, mRNA expression was increased in primary BECs from children with severe asthma compared with that seen in control children and was related to impaired interferon induction and increased viral release. **A**, SOCS1 mRNA levels were increased at baseline in children with STRA compared with NANA subjects. No differences between NANA subjects and children with STRA were observed for

## Induction of SOCS1 inhibited interferon induction *in vivo*

We next investigated the importance of SOCS1 in regulating rhinovirus-induced interferon *in vivo* using *IFN- $\gamma$ <sup>-/-</sup>* and *SOCS1<sup>-/-</sup>IFN- $\gamma$ <sup>-/-</sup>* mice. Mice were pretreated with IL-13 for 8 hours to enhance SOCS1 levels before rhinovirus infection (see Fig E5, A, in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). IL-13 pretreatment significantly enhanced SOCS1 mRNA expression in the lungs of *IFN- $\gamma$ <sup>-/-</sup>* mice by approximately 3-fold (see Fig E5, B). As expected, there was no SOCS1 expression in SOCS1-deficient mice. On rhinovirus infection, IL-13-pretreated *IFN- $\gamma$ <sup>-/-</sup>* mice in which SOCS1 was induced had significantly deficient IFN- $\alpha$ , trends toward deficient IFN- $\lambda$ , and significantly deficient RANTES/CCL5 (an interferon-inducible chemokine) in BAL fluid when compared with IL-13-pretreated *SOCS1<sup>-/-</sup>IFN- $\gamma$ <sup>-/-</sup>* mice, in which SOCS1 could not be induced (Fig 3, C). Consistent with our observation that enhanced SOCS1 expression substantially enhanced rhinovirus induction of the CXCL8 promoter in human BECs *in vitro* (see Fig E4, A), enhanced SOCS1 expression significantly augmented rhinovirus induction of the mouse CXCL8 homologues keratinocyte-derived chemokine (KC)/CXCL1 and LPS-induced CXC chemokine (LIX)/CXCL5 *in vivo* (Fig 3, C).

## Increased SOCS1 levels in BECs from asthmatic children were associated with interferon deficiency

BECs from children with STRA with confirmed rhinovirus-induced interferon deficiency<sup>14</sup> were used to investigate whether SOCS1 levels are increased in primary BECs from patients with severe asthma. We also sought to establish whether there were relationships between SOCS1 levels, interferon deficiency, and viral replication. *SOCS1*, but not *SOCS3*, mRNA expression levels were increased (approximately 8- to 9-fold) in unstimulated and uninfected primary human BECs from children with severe asthma compared with those in BECs from NANA control subjects (Fig 4, A). *SOCS1* mRNA levels in the unstimulated and uninfected cells were significantly inversely correlated with *IFN- $\lambda$ 1* and *IFN- $\lambda$ 2/3* mRNA induction by polyI:C, with a similar but nonsignificant trend for *IFN- $\beta$*  (Fig 4, B) and, importantly, with induction of all 3 interferon subtypes by RV16 (Fig 4, C). However, RV1B showed no significant correlation (Fig 4, D). Baseline *SOCS1* mRNA levels correlated positively with RV1B release at 48 hours after infection in BECs but did not correlate with RV16 release (Fig 4, E).


## SOCS1 suppression of interferons required SOCS1 nuclear translocation

SOCS1 can prevent nuclear factor  $\kappa$ B (NF- $\kappa$ B) signaling by entering the nucleus through a C-terminal proximal nuclear localization sequence (NLS) and targeting NF- $\kappa$ B p65 for proteasomal degradation through the C-terminal SOCS box.<sup>32</sup>

Therefore we hypothesized that SOCS1 might suppress rhinovirus-induced interferon induction by translocating into the nucleus and initiating proteasomal degradation of transcription factors required for interferon induction. To investigate the role of nuclear translocation of SOCS1 and of the SOCS box, we used vectors expressing green fluorescent protein (GFP)-tagged full-length wild-type human SOCS1 (SOCS1wt) and 2 mutants. The mutants included SOCS1 truncations with both the NLS and the SOCS box deleted (Q108X) or with a deleted SOCS box alone, leaving the NLS intact (R172X; Fig 5, A).<sup>32</sup> We found that the SOCS1 mutant that lacked the NLS (Q108X) was indeed unable to translocate to the nucleus; however, both SOCS1wt and R172X, which had a deleted SOCS box but intact NLS, were able to translocate to the nucleus (Fig 5, A). We then tested the ability of these constructs to suppress rhinovirus induction of interferons in BEAS-2B cells and found that the construct lacking the NLS (Q108X) had lost its ability to suppress rhinovirus-induced IFN- $\beta$  and IFN- $\lambda$  promoter activation, whereas fully intact SOCS1 (SOCS1wt containing both the NLS and the SOCS box) and R172X (containing the NLS but lacking the SOCS box) were still suppressive (Fig 5, B). Furthermore, SOCS1wt, but neither Q108X nor R172X, suppressed interferon-induced ISRE promoter activation. This definitively proves that SOCS1-mediated suppression of rhinovirus-induced interferon is NLS dependent but SOCS box independent and therefore distinct from interferon-induced ISRE activation, which is dependent on both the NLS and the SOCS box (Fig 5, B). Furthermore, the requirement for nuclear localization for both rhinovirus- and interferon-induced responses was supported with a full-length SOCS1 construct containing mutated NLS residues ( $\Delta$ 6RA), which was impaired in its ability to enter the nucleus and exhibited a less suppressive effect on interferon induction when compared with SOCS1wt (see Fig E6, B-D, in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). SOCS1wt, R172X, and Q108X proteins were expressed at similar levels, as determined by using Western blotting (see Fig E6, A).

Because the construct (R172X) lacking the SOCS box (which is required for initiation of proteasomal degradation) still suppressed rhinovirus-induced interferon promoter activation (Fig 5, B), this suggested that SOCS1-mediated suppression of rhinovirus-induced interferon was independent of proteasomal degradation. Therefore we next investigated whether pretreatment with the 28S proteasome inhibitor MG132 would be able to prevent SOCS1-mediated inhibition of rhinovirus-induced interferon. At a concentration of 1  $\mu$ mol/L, MG132 significantly suppressed rhinovirus-induced NF- $\kappa$ B promoter activation, which is dependent on proteasomal degradation of I $\kappa$ B and therefore sensitive to this inhibitor (Fig 5, C). We found that neither the 1  $\mu$ mol/L dose nor the 2  $\mu$ mol/L dose had any effect on SOCS1-mediated suppression of rhinovirus-induced IFN- $\beta$  or IFN- $\lambda$  promoter activation, confirming that proteasomal

SOCS3 mRNA levels. \* $P$  < .05. ns, Not significant. **B**, PolyI:C induced IFN- $\beta$ , IFN- $\lambda$ 1, and IFN $\lambda$ 2/3 mRNA levels 8 hours after treatment negatively correlated with baseline SOCS1 mRNA levels. **C**, RV16-induced IFN- $\beta$ / $\lambda$ 1/ $\lambda$ 2/3 mRNA levels 24 hours after infection negatively correlated with baseline SOCS1 mRNA levels. **D**, RV1B-induced IFN- $\beta$ / $\lambda$ 1/ $\lambda$ 2/3 mRNA levels 24 hours after infection showed trends toward a negative correlation with baseline SOCS1 mRNA levels. **E**, RV16 and RV1B release 48 hours after infection, as measured by means of titration in HeLa cells, positively correlated with baseline SOCS1 mRNA levels.



degradation is not involved in SOCS1-mediated suppression of rhinovirus-induced interferon induction (Fig 5, D).

Finally, to determine whether nuclear SOCS1 levels were increased in asthmatic patients, we re-evaluated protein staining for SOCS1 in bronchial biopsy specimens from patients with mild-to-moderate AA and nonatopic healthy subjects and specifically assessed only nuclear staining. Nuclear SOCS1 staining was clearly observed in the BEC layer in these biopsy specimens, with significantly higher levels of SOCS1 nuclear staining in patients with AA compared with healthy subjects (Fig 5, E). Furthermore, numbers of nuclear SOCS1-positive cells positively correlated with serum total IgE levels in these subjects. Nuclear SOCS1 levels did not correlate with exacerbation numbers (data not shown).

## DISCUSSION

Impaired interferon induction in response to rhinovirus and other viral infections *ex vivo* has been reported recently and in several studies is related to markers of underlying asthma severity.<sup>6,7,11,13,33</sup> Furthermore, trends toward a higher viral load in asthmatic patients compared with that seen in healthy control subjects have been observed *in vivo*.<sup>5</sup> The mechanism or mechanisms responsible for this impaired induction of interferon are unknown. Here we describe increased expression of SOCS1 in asthmatic patients, the importance of its nuclear rather than cytoplasmic function, and its role in deficient interferon induction. These data together identify avenues to inhibit the expression or function of SOCS1 as potential therapies for asthma exacerbations, boosting deficient interferon responses and potentially suppressing harmful inflammatory chemokine induction.

Previous studies of SOCS1 expression in asthmatic patients have led to contradictory findings.<sup>22,24</sup> The induction and role of SOCS1 in airway epithelium has been poorly studied to date, with a single study reporting increased *SOCS1* mRNA expression in response to IFN- $\gamma$  stimulation of primary BECs.<sup>34</sup> We found that a number of stimuli increased *SOCS1* mRNA expression, including T<sub>H</sub>2 and proinflammatory cytokine levels, rhinovirus, and polyI:C. Uninfected (stable) patients with AA had increased SOCS1 protein staining in bronchial biopsy specimens compared with nonasthmatic subjects, which we argue was likely a result of

ongoing allergic airways inflammation. The observed increased expression in patients with stable asthma would mean that on viral infection, the ability to respond with rapid interferon induction would be impaired. This is entirely in keeping with the delayed and quantitatively impaired early interferon induction reported in studies identifying interferon deficiency in asthmatic patients.<sup>6,13,14</sup>

We further found that SOCS1 expression was induced by exacerbation-related and virus-induced proinflammatory cytokines, polyI:C, and rhinovirus infection of BECs. This strongly supports the idea that SOCS1 expression is likely to be further upregulated as asthma exacerbations progress, which is consistent with observations of substantially impaired interferon responses and greater viral replication in lung cells at later time points,<sup>6,7,13,14</sup> increased duration of rhinovirus-related lower airways symptoms in asthmatic patients,<sup>4</sup> and strong relationships between impaired interferon induction and asthma exacerbation severity *in vivo*.<sup>7</sup>

In cell lines SOCS1 can suppress interferon induction by influenza viruses.<sup>28</sup> In the present study we only investigated SOCS1 expression and the role of SOCS1 in rhinovirus infection. Although rhinovirus is the main trigger of asthma exacerbations, other viruses can cause asthma exacerbations, and whether this is in part due to impaired antiviral immunity in lung epithelial cells remains unclear. Therefore we cannot claim that the role of SOCS1 in suppressing virus-induced interferon levels is limited to rhinovirus infection. It would be of interest to the field to examine the role of SOCS1 in other respiratory tract virus infections; of interest, impaired interferon induction has been observed in PBMCs and dendritic cells from patients with respiratory syncytial virus and influenza, respectively.<sup>8,9</sup> Recently, Spann et al<sup>35</sup> showed higher viral loads in respiratory syncytial virus- and metapneumovirus-infected tracheal epithelial cells from wheezy children, but no impairments in type I or type III interferons were observed.<sup>35</sup> Clearly, more studies are required to determine whether impaired interferon induction is mostly associated with rhinovirus infection and whether SOCS1 can impair interferon induction by other respiratory tract viruses in primary BEC *ex vivo* models. Therefore our data potentially explain why interferon is impaired in asthmatic patients but does not explain why rhinovirus is the most frequent cause of asthma exacerbations.

**FIG 5.** SOCS1-mediated suppression of rhinovirus-induced interferon expression required nuclear translocation but not proteasome-mediated degradation. **A**, Confocal microscopy showed nuclear localization of SOCS1wt and the R172X mutant, whereas the Q108X mutant showed only cytoplasmic localization. All images used the  $\times 60$  objective. Bar = 10- $\mu$ m scale. DAPI, 4'-6-Diamidino-2-phenylindole dihydrochloride. **B**, SOCS1wt and R172X both suppressed RV1B-induced interferon promoter activation, whereas Q108X did not. SOCS1wt, but neither Q108X nor R172X, suppressed IFN- $\beta$ -induced minimal ISRE-responsive promoter activation. \* $P < .05$  and \*\*\* $P < .001$ , as indicated and versus GFP empty vector-transfected, RV1B-infected, or IFN- $\beta$ -treated group. +++ $P < .001$  versus SOCS1wt-transfected rhinovirus-infected or IFN- $\beta$ -treated cells. ns, Not significant (upper ns, not significant vs SOCS1wt, RV1B-infected, or IFN- $\beta$ -treated cells; lower ns, not significant vs GFP, RV1B-infected, or IFN- $\beta$ -treated cells). **C**, MG132 inhibited RV1B-induced NF- $\kappa$ B activation. \*\* $P < .01$  and \*\*\* $P < .001$  versus the RV1B-infected untreated group. **D**, MG132 had no effect on SOCS1-mediated suppression of rhinovirus-induced IFN- $\lambda$ 1 or IFN- $\beta$  promoter activation. \* $P < .05$  and \*\*\* $P < .001$ , as indicated and versus the pORF-transfected RV1B-infected untreated group. + $P < .05$  and +++ $P < .001$  versus the pORF-transfected RV1B-infected group treated with 2  $\mu$ mol/L MG132.  $\times P < .05$  and  $\times \times P < .001$  versus the pORF-transfected RV1B-infected untreated group. **E**, Increased nuclear SOCS1 expression in BECs was observed in patients with AA compared with that seen in NANA subjects, and nuclear SOCS1 staining correlated with IgE levels in these subjects. All images used the  $\times 60$  objective. Black arrows indicate nuclear SOCS1 staining. Bar = 10- $\mu$ m scale. \* $P < .05$ .

The increased SOCS1 protein levels correlated with clinical markers of asthma (PC<sub>20</sub>) and also numbers of positive skin prick test responses, suggesting a relationship between SOCS1 expression and AA. At this point, we cannot definitively conclude whether SOCS1 expression is increased because of asthma, atopy, or both. Furthermore, because our study numbers remain small, there is a need for further studies with larger patient numbers to confirm whether SOCS1 expression is related to clinical markers of asthma or atopy. We speculated that bronchial epithelial SOCS1 expression might be increased because of ongoing airway inflammation, and our findings that SOCS1 expression was induced by T<sub>H</sub>2 and non-T<sub>H</sub>2 cytokines support this hypothesis. Because the non-T<sub>H</sub>2 cytokines TNF- $\alpha$  and IL-1 $\beta$  also induced SOCS1, this is unlikely to be a strictly T<sub>H</sub>2-dependent process. However, the link between SOCS1 and T<sub>H</sub>2 responses has been previously established. SOCS1 is a negative regulator of T<sub>H</sub>2 responses.<sup>21,23</sup> SOCS1 has a known role in hematopoietic cells. Increased SOCS1 levels in hematopoietic cells act to counter excessive T<sub>H</sub>2 outgrowth, whereby in BECs excessive T<sub>H</sub>2 cytokine signaling might also induce SOCS1, but our results suggest this likely hampers epithelium-derived innate interferon induction and immunity to viruses. Indeed, we found that bronchial epithelial SOCS1 expression correlated with the number of positive skin prick test responses and airway hyperresponsiveness but not exacerbation numbers, suggesting that SOCS1 can be increased in response to but not limited to allergic inflammation. In support, Baraldo et al<sup>11</sup> have shown a clear association between impaired rhinovirus-induced interferon induction in asthmatic patients and increased T<sub>H</sub>2 cytokine expression in the bronchial mucosa. The antagonistic effects of interferons on T<sub>H</sub>2 signaling and the allergic cascade and *vice versa* is also underscored by other studies.<sup>9,12,36-39</sup> Further studies are required to see whether impaired interferon induction is consistent with other markers of non-T<sub>H</sub>2 inflammation. Therefore we argue that therapies reducing T<sub>H</sub>2, TNF, or IL-1 $\beta$  signaling could enhance antiviral immunity in asthmatic patients. The latter hypothesis is supported by the observed therapeutic effect in selected populations that anti-T<sub>H</sub>2 therapies have recently been shown to have on asthma exacerbations.<sup>29,30,40</sup> Although clinical studies investigating the effects of anti-IL-1 $\beta$  therapies are yet to be performed, the effects of TNF therapy on asthma exacerbation rates have been reported by just one study.<sup>41</sup> Anti-TNF therapy (etanercept) had no effect versus placebo on the asthma exacerbation rate; however, this rate was extremely low across both groups (n = 1 each), and therefore no definitive conclusion can be reached. Considering the findings in this article, the effects of anti-IL-1 $\beta$  and anti-TNF therapy on interferon responses and asthma exacerbation rates and severity are warranted and would be of interest.

We found that SOCS1 suppressed virus-induced interferon induction but augmented IL-8/CXCL8 *in vitro* and augmented KC/CXCL1 and LIX/CXCL5 in mice *in vivo*. Having excess SOCS1 in BECs could be doubly deleterious in patients with asthma exacerbations in that beneficial antiviral pathways mediated by interferons are suppressed and harmful pro-inflammatory responses are augmented. These data clearly point to approaches that will inhibit the expression or function of SOCS1 as novel strategies for therapeutic intervention in patients with asthma exacerbations.

We found that SOCS1 was a potent suppressor of virus-induced type I and type III interferon induction. We originally

attempted to grow tracheal epithelial cells from *SOCS1*<sup>-/-</sup> mice but found these difficult to grow with established protocols. This omission is an unfortunate limitation of our study. We then opted to use BAL macrophages from *SOCS1*<sup>-/-</sup> mice and found that *SOCS1*<sup>-/-</sup> mice had enhanced interferon induction on rhinovirus infection compared with wild-type mice, enforcing the idea that SOCS1 is a negative regulator of virus-induced interferon. Consistent with the literature in other systems,<sup>25,26</sup> we also found that SOCS1 regulated interferon-induced signaling in BECs. IFN- $\alpha/\beta/\lambda$ s can all act as interferon-stimulated genes (ISGs), being induced by IFN- $\beta$  and thus providing a positive feedback loop,<sup>42,43</sup> and we observed that SOCS1 inhibited IFN- $\beta$ -induced IFN- $\beta$  and IFN- $\lambda$ 1 promoter activation. SOCS1-mediated inhibition of interferon receptor signaling has been shown to be dependent on the SOCS box.<sup>26,44</sup> The SOCS box deletant R172X, which could undergo nuclear translocation, profoundly inhibited rhinovirus-induced IFN- $\beta$  and IFN- $\lambda$  promoter activation but not that of an ISRE-containing promoter, which is dependent on interferon receptor signaling, therefore proving that this SOCS1 mutant suppresses virus-induced rather than interferon-induced interferon induction. These data are consistent with the known requirement for the SOCS box in SOCS-mediated suppression of interferon receptor signaling.

In contrast, SOCS1 suppression of rhinovirus-induced interferon induction was independent of the SOCS box and did not require proteasomal degradation. SOCS1-mediated suppression of rhinovirus-induced interferon induction was very clearly dependent on nuclear localization because the SOCS1 construct unable to localize to the nucleus (Q108X) was unable to suppress rhinovirus-induced interferon promoter activation, and another construct with the NLS mutated ( $\Delta$ 6RA) also demonstrated a significantly less suppressive effect than SOCS1wt. Importantly, and supporting the specific role for nuclear expression of SOCS1, we were able to show that bronchial epithelial expression of nuclear SOCS1 was significantly increased in asthmatic patients. Further studies will be required to understand the specific mechanism of how nuclear SOCS1 suppresses virus-induced interferon induction. Our present studies clearly identify suppression of virus-induced interferon induction as a novel function of nuclear SOCS1 and, independent of its previous known nuclear function, SOCS box mediated proteasomal degradation.

In summary, our data provide novel findings relating to the requirement of nuclear SOCS1 to exert novel effects of suppression of virus-induced interferon induction. The data further demonstrate nuclear SOCS1 plays an important role in regulation of interferon deficiency in patients with AA, providing a mechanistic explanation for this important phenomenon. Because SOCS1 inhibits both virus- and interferon-induced interferon induction through distinct mechanisms, this makes inhibition of SOCS1 an attractive therapeutic target capable of restoring deficient interferon responses. The ability of SOCS1 to enhance proinflammatory responses adds further attractiveness to SOCS1 as a therapeutic target. Thus these studies provide evidence for SOCS1 as a novel therapeutic target for asthma exacerbations, a major unmet medical need.

We thank Mellisa Dixon and Tom Burgoyne for technical support.

## Key messages

- **Increased SOCS1 levels in cells from asthmatic patients impair interferon induction in asthmatic patients through its nuclear localization. However, SOCS1 did not impair virus-induced inflammatory mediators, showing specificity for antiviral immunity.**
- **This represents a novel mechanism explaining interferon deficiency in asthmatic patients, shows a new nuclear function of SOCS1, and identifies SOCS1 as an important therapeutic target for asthma exacerbations.**

## REFERENCES

- O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med* 2009;179:19-24.
- Johnston SL, Pattermore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995;310:1225-9.
- Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebabdz T, Keith PK, et al. The September epidemic of asthma exacerbations in children: a search for etiology. *J Allergy Clin Immunol* 2005;115:132-8.
- Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. *Lancet* 2002;359:831-4.
- Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebabdz T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. *Proc Natl Acad Sci U S A* 2008;105:13562-7.
- Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* 2005;201:937-47.
- Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat Med* 2006;12:1023-6.
- Gehlhar K, Bilitewski C, Reinitz-Rademacher K, Rohde G, Bufe A. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. *Clin Exp Allergy* 2006;36:331-7.
- Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, et al. Counterregulation between the TcEpsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. *J Immunol* 2010;184:5999-6006.
- Iikura K, Katsunuma T, Saika S, Saito S, Ichinohe S, Ida H, et al. Peripheral blood mononuclear cells from patients with bronchial asthma show impaired innate immune responses to rhinovirus in vitro. *Int Arch Allergy Immunol* 2011;155(suppl 1):27-33.
- Baraldo S, Contoli M, Bazzan E, Turato G, Padovani A, Marku B, et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. *J Allergy Clin Immunol* 2012;130:1307-14.
- Durrani SR, Montville DJ, Pratt AS, Sahu S, Devries MK, Rajamanickam V, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. *J Allergy Clin Immunol* 2012;130:489-95.
- Sykes A, Edwards MR, Macintyre J, Del Rosario A, Bakhsoliani E, Trujillo-Torralbo MB, et al. Rhinovirus 16-induced IFN- $\alpha$  and IFN- $\beta$  are deficient in bronchoalveolar lavage cells in asthmatic patients. *J Allergy Clin Immunol* 2012;129:1506-14.e6.
- Edwards MR, Regamey N, Vareille M, Kieninger E, Gupta A, Shoemark A, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. *Mucosal Immunol* 2012;6:797-806.
- Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. *Thorax* 2014;69:240-6.
- Thomas BJ, Lindsay M, Dagher H, Freezer NJ, Li D, Ghildyal R, et al. Transforming growth factor-beta enhances rhinovirus infection by diminishing early innate responses. *Am J Respir Cell Mol Biol* 2009;41:339-47.
- Bedke N, Sammut D, Green B, Kehagia V, Dennison P, Jenkins G, et al. Transforming growth factor-Beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response. *PLoS One* 2012;7:e44580.
- Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. *Immunity* 2001;14:535-45.
- Knosp CA, Carroll HP, Elliott J, Saunders SP, Nel HJ, Amu S, et al. SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. *J Exp Med* 2011;208:1523-31.
- Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. *Nat Med* 2003;9:1047-54.
- Lee C, Kolesnik TB, Caminschi I, Chakravorty A, Carter W, Alexander WS, et al. Suppressor of cytokine signalling 1 (SOCS1) is a physiological regulator of the asthma response. *Clin Exp Allergy* 2009;39:897-907.
- Fukuyama S, Nakano T, Matsumoto T, Oliver BG, Burgess JK, Moriwaki A, et al. Pulmonary suppressor of cytokine signaling-1 induced by IL-13 regulates allergic asthma phenotype. *Am J Respir Crit Care Med* 2009;179:992-8.
- Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. *J Immunol* 2002;168:3181-7.
- Harada M, Nakashima K, Hirota T, Shimizu M, Doi S, Fujita K, et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. *Am J Respir Cell Mol Biol* 2007;36:491-6.
- Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. *Nat Immunol* 2006;7:33-9.
- Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. *J Biol Chem* 2011;286:33811-8.
- Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, et al. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. *Biochem Biophys Res Commun* 2004;320:1007-14.
- Pothlichet J, Chignard M, Si-Tahar M. Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. *J Immunol* 2008;180:2034-8.
- Corren J, Lemanska RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebelrikizumab treatment in adults with asthma. *N Engl J Med* 2011;365:1088-98.
- Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 2013;368:2455-66.
- Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. *Allergy* 2009;64:375-86.
- Strebosky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. *FASEB J* 2010;25:863-74.
- Uller L, Leino M, Bedke N, Sammut D, Green B, Lau L, et al. Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial cells from donors with asthma. *Thorax* 2010;65:626-32.
- Heller NM, Matsukura S, Georas SN, Boothby MR, Rothman PB, Stellato C, et al. Interferon-gamma inhibits STAT6 signal transduction and gene expression in human airway epithelial cells. *Am J Respir Cell Mol Biol* 2004;31:573-82.
- Spann KM, Baturcam E, Schagen J, Jones C, Straub CP, Preston FM, et al. Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy. *Thorax* 2014;69:918-25.
- Pritchard AL, Carroll ML, Burel JG, White OJ, Phipps S, Upham JW. Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. *J Immunol* 2012;188:5898-905.
- Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. *EMBO Mol Med* 2011;3:348-61.
- Sriram U, Biswas C, Behrens EM, Dinnall JA, Shivers DK, Monestier M, et al. IL-4 suppresses dendritic cell response to type I interferons. *J Immunol* 2007;179:6446-55.
- Edwards S, Jones C, Leishman AJ, Young BW, Matsui H, Tomizawa H, et al. TLR7 Stimulation of APCs results in inhibition of IL-5 through type I IFN and notch signaling pathways in human peripheral blood mononuclear cells. *J Immunol* 2013;190:2585-92.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012;380:651-9.

41. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. *Thorax* 2008;63: 584-91.
42. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. *Proc Natl Acad Sci U S A* 1995;92: 11284-8.
43. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. *EMBO J* 1998;17:6660-9.
44. Koelsche C, Strebovsky J, Baetz A, Dalpke AH. Structural and functional analysis of a nuclear localization signal in SOCS1. *Mol Immunol* 2009;46:2474-80.

## METHODS

### Viruses, cells, and reagents

Rhinovirus serotypes 16 and 1B were grown in Ohio HeLa cells and UV inactivated, as previously described.<sup>E1</sup> In some experiments RV1B and RV16 were filtered by means of centrifugation (at 12,000 rpm for 5 minutes) through a filter with a 30-kDa molecular weight cutoff (Amicon, Dublin, Ireland), thus producing a virus-free filtrate. RV1B used for *in vivo* purposes was concentrated and purified, as previously described.<sup>E2</sup> BEAS-2B cells were maintained in RPMI 1640 medium with 10% FCS. Primary BECs (Clonetics, Wokingham, United Kingdom) from nonsmoking nonasthmatic donors were grown according to the manufacturer's recommended protocol. PolyI:C (Sigma-Aldrich, Dorset, United Kingdom) was made up at 1 mg/mL in water and stored at  $-80^{\circ}\text{C}$ . Recombinant mouse IL-13 and recombinant human IL-4, IL-13, TNF- $\alpha$ , and IL-1 $\beta$  (R&D Systems, Abingdon, United Kingdom) were made up in sterile PBS containing 0.1% BSA and stored at  $-80^{\circ}\text{C}$ . SOCS1-pORF and pORF control vector were purchased from InvivoGen (Nottingham, United Kingdom). The wild-type SOCS1-GFP, GFP empty vector, and SOCS1-GFP tagged mutants R172X, Q108X, and  $\Delta$ 6RA were used, as previously described.<sup>E3</sup> The  $-125$ -bp fragment of the human IFN- $\beta$  promoter in pGL3 was a kind gift from T. Fujita, and the IFN- $\lambda$ 1 promoter was made by cutting the 1kb human IFN- $\lambda$ 1 promoter<sup>E4</sup> and subcloning into vector pGL3 (Promega, Madison, Wis). The minimal ISRE-containing promoters were purchased from Clontech (Saint-Germain-en-Laye, France). The minimal STAT1/2-containing promoter was purchased from Panomics (Vignate-Milano, Italy). All plasmids were grown in *Escherichia coli*, plasmid purified with Maxiprep (Qiagen, Crawley, United Kingdom), and stored in water at 1  $\mu\text{g}/\text{mL}$  at  $-80^{\circ}\text{C}$ .

### Patients with mild-to-moderate AA and NANA subjects

Bronchial biopsy specimens were obtained at bronchoscopy from a recent clinical study performed in our laboratory, which reported deficient rhinovirus-induced IFN- $\alpha/\beta$  responses in BAL cells from adults with AA compared with nonatopic healthy control adult subjects.<sup>E5</sup> Inclusion and exclusion criteria have been reported.<sup>E5</sup> Numbers of exacerbations in the last year were reported, as previously described.<sup>E5</sup> Table E1 provides the clinical characteristics of the participants providing bronchial biopsy specimens for analysis in this study. All subjects provided written informed consent, and ethics approval for this study was given by St Mary's NHS Trust Research Ethics Committee (08/H0712/39 and 07/Q0403/20, Professor S. L. Johnston).

### BEC culture from children with STRA and NANA donors

BECs were obtained through bronchoscopies performed on 11 pediatric patients with STRA, as previously described.<sup>E6</sup> NANA control children were recruited through the Royal Brompton Hospital and Children's Hospital in Bern, Switzerland. The control children ( $n = 11$ ) had no personal or family history of asthma and no record of food allergy, rhinitis, or eczema. Use of bronchial brushings from patients with severe asthma and control children was approved by both the Royal Brompton NHS Trust (02/302, Professor A. Bush) and the Ethics Committee for the Canton of Bern and University Children's Hospital Bern, Switzerland (77/09, A/Professor N. Regamey). BECs were grown from bronchial brushings in bronchial epithelial cell growth medium, as previously described.<sup>E6</sup> Table E2 provides the clinical characteristics of the participants in the severe asthma study.

### Animal models

IFN- $\gamma^{-/-}$  and SOCS1 $^{-/-}$ IFN- $\gamma^{-/-}$  mice on a C57BL/6 background were bred and used, as previously described.<sup>E7</sup> All breeding and experimentation was performed according to regulations outlined by the Home Office UK. The mice were lightly anesthetized with isoflurane and treated and infected intranasally. Mice were treated with 0.5  $\mu\text{g}$  of recombinant mouse IL-13 (R&D Systems) 8 hours before challenge with a  $5 \times 10^6$  median tissue culture infectious dose of RV1B, as previously described.<sup>E2</sup> IFN- $\gamma^{-/-}$  and

IFN- $\gamma^{-/-}$ SOCS1 $^{-/-}$  C57BL/6 mouse BAL macrophages were harvested by means of lavage and placed in RPMI medium with 10% FCS before plating.

### Treatment of cells and infection with rhinovirus

BEAS-2B cells, primary human BECs (Clonetics), and primary BECs obtained from asthmatic and nonasthmatic donors were infected with RV1B or RV16 (multiplicity of infection = 1). BECs (Clonetics) were treated with IL-4 and IL-13 at 50 ng/mL and IL-1 $\beta$  and TNF- $\alpha$  at 10 ng/mL (R&D Systems) or polyI:C diluted in BEBM medium and used at 1  $\mu\text{g}/\text{mL}$  for various time points. Mouse BAL macrophages were counted, plated at  $1 \times 10^6$  cells per well, and infected with RV1B as above and harvested at the indicated time points.

### Transfection of human BECs with plasmid DNA and reporter assays

Confluent monolayers of BEAS-2B cells and primary human BECs in 12-well plates (Nunc, Rochester, NY) were transiently transfected with plasmid DNA and luciferase measured by using the Dual luciferase assay (Promega), as previously described.<sup>E8</sup>

### SOCS1 immunohistochemistry

SOCS1- and SOCS3-positive cells were detected by using the EnVision Peroxidase staining method. After dewaxing, the sections were incubated with peroxidase-blocking solution and probed with primary rabbit anti-SOCS1 (catalog no. 18-003-43725; GenWay Biotech, San Diego, Calif) and rabbit anti-SOCS3 (catalog no. E16854; Spring Bioscience, Pleasanton, Calif) overnight at  $4^{\circ}\text{C}$ . The sections were then incubated with EnVision goat anti-rabbit antibody for 30 minutes (K4003; DAKO, Glostrup, Denmark). After washing, sections were incubated with chromogen (liquid diaminobenzidine and peroxide buffer). Slides were counterstained with hematoxylin to provide nuclear and morphologic detail and mounted. Irrelevant rabbit IgG (Sigma-Aldrich) was used for the primary layer as a negative control procedure. The slides were blinded, and the immunostaining intensity for total SOCS1 and SOCS3 in the airway epithelium was semiquantitatively scored as 0 to 3 (0 = negative, 1 = weak staining, 2 = moderate staining, and 3 = strong staining). The SOCS1 and SOCS3 nuclear staining of epithelial cells was counted from 2 to 3 bronchial biopsy specimens per subject, and the average was used for statistical analyses. The data for epithelial nuclear counts were expressed as the number of positive nuclei per 0.1  $\text{mm}^2$  of epithelium.

### Confocal microscopy

BEAS-2B cells were seeded into transwell plates (Nunc) and transfected with GFP-tagged SOCS1 plasmids. After 24 hours, cells were fixed in 4% paraformaldehyde and counterstained with Evans Blue (red for both cytoplasm and nuclear) and 4'-6-diamidino-2-phenylindole dihydrochloride (blue for nuclear). The cells were observed at room temperature, and images were captured with a Zeiss LSM 510 inverted confocal microscope with LSM 510 software (Zeiss, Oberkochen, Germany).

### RNA isolation, cDNA synthesis, and TaqMan real-time PCR

Total RNA isolation, cDNA synthesis, and TaqMan PCR were performed, as previously described.<sup>E6</sup> All data are presented as the copy number per 1  $\mu\text{L}$ . Primer and probe sequences are presented in Table E3.

### SDS-PAGE and Western blotting

Total protein lysates were run on 16% Tris glycine polyacrylamide gels and transferred onto nitrocellulose membranes (Invitrogen, Paisley, United Kingdom), blocked in 5% skimmed milk, and probed with antibodies specific for human SOCS1 at 500 ng/mL (Millipore, Temecula, Calif) and human SOCS3 at 200 ng/mL (Santa Cruz Biotechnology, Santa Cruz, Calif). GFP-tagged SOCS1 proteins were analyzed by means of Western blotting with anti-GFP (Abcam, Cambridge, United Kingdom) at 1  $\mu\text{g}/\text{mL}$ .

Anti- $\alpha$ -tubulin (1  $\mu$ g/mL, Santa Cruz Biotechnology) was used to detect  $\alpha$ -tubulin as a load control. The secondary antibody used was goat anti-mouse horseradish peroxidase at 0.08  $\mu$ g/mL (Santa Cruz Biotechnology). Blots were developed with ECL (GE Healthcare, Fairfield, Conn).

## ELISA


ELISAs for mouse IFN- $\alpha$ , IFN- $\lambda$ , KC/CXCL1, RANTES/CCL5, and LIX/CXCL5 were from R&D Systems and used according to the manufacturer's recommended protocol.

## Statistical analysis


Nonclinical data are represented as means  $\pm$  SEMs. At least 4 experiments were performed for *in vitro* and *ex vivo* experiments. For *in vivo* experiments, 3 experiments were performed with 4 to 7 mice per group. Time-course data in BECs and mice were analyzed by using 2-way ANOVA at a 95% CI with the Bonferroni multiple comparison test. Reporter assay and *ex vivo* BAL macrophage data were analyzed by using 1-way ANOVA at a 95% CI if significant, and differences were pinpointed with the Bonferroni multiple comparison test. Clinical data are represented as medians and were analyzed by using the Mann-Whitney *U* test. Correlations in clinical data were analyzed by using the Spearman test. A *P* value of less than .05 was considered statistically different.

## REFERENCES


- E1. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. *J Biol Chem* 1999;274:9707-20.
- E2. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. *Nat Med* 2008;14:199-204.
- E3. Strebovsky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. *FASEB J* 2010;25:863-74.
- E4. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. *J Immunol* 2007;179:3434-42.
- E5. Sykes A, Edwards MR, Macintyre J, Del Rosario A, Bakhsooliani E, Trujillo-Torralbo MB, et al. Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. *J Allergy Clin Immunol* 2012;129:1506-14.e6.
- E6. Edwards MR, Regamey N, Vareille M, Kieninger E, Gupta A, Shoemark A, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. *Mucosal Immunol* 2012;6:797-806.
- E7. Lee C, Kolesnik TB, Caminschi I, Chakravorty A, Carter W, Alexander WS, et al. Suppressor of cytokine signalling 1 (SOCS1) is a physiological regulator of the asthma response. *Clin Exp Allergy* 2009;39:897-907.
- E8. Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, et al. Defining critical roles for NF-kappaB p65 and type I interferon in innate immunity to rhinovirus. *EMBO Mol Med* 2012;4:1244-60.




**FIG E1.** Densitometry of SOCS1 Western blots in Fig 1, effects of SOCS1 mRNA induction by rhinovirus after UV inactivation and filtration, and dose-dependent induction of SOCS1 mRNA by rhinovirus. **A-C**, Primary human BECs were treated with IL-4 or IL-13 (Fig E1, A) or TNF- $\alpha$  or IL-1 $\beta$  (Fig E1, B) or were infected with RV1B, RV16, or polyI:C (1  $\mu$ g/mL; Fig E1, C), and total protein was harvested over time and plotted versus  $\alpha$ -tubulin as a control protein ( $n = 1$  experiment for all induced SOCS1 protein). **D** and **E**, BECs were infected with RV16 (Fig E1, D), UV-inactivated RV16, or filtered RV16, or RV1B (Fig E1, E). *F-RV1B*, Filtered RV1B; *UV-RV1B*, UV-inactivated RV1B. UV-inactivated and rhinovirus-filtered (virus-free) preparations both showed a reduction in SOCS1 mRNA expression. **F** and **G**, BECs infected with RV16 (Fig E1, F) or RV1B (Fig E1, G) showed dose-dependent inductions of SOCS1 mRNA. \* $P < .05$ , \*\* $P < .01$ , and \*\*\* $P < .001$ , as indicated or versus rhinovirus treatment, by means of 1-way ANOVA. *ns*, Not significant. There were 3 to 4 experiments from BECs derived from 3 to 4 healthy control donors.




**FIG E2.** SOCS3 mRNA and protein were induced in BECs by rhinovirus and polyI:C. Primary human BECs were infected with RV1B, RV16, or polyI:C (1 μg/mL), and total RNA and total protein were harvested over time. RV1B (**A**), RV16 (**B**), and polyI:C (**C**) all induced SOCS3 mRNA and protein in a time-dependent manner. Values are presented as means ± SEMs (n = 4 experiments). \*\**P* < .01 versus medium treatment, 2-way ANOVA.






**FIG E4.** SOCS1 overexpression increased RV1B-, IL-1 $\beta$ - and TNF- $\alpha$ -induced CXCL8 promoter activation. BEAS-2B cells were seeded and transfected with SOCS1 or the empty vector control pORF and infected with RV1B or treated with 10 ng/mL IL-1 $\beta$  or TNF- $\alpha$ . SOCS1 overexpression increased RV1B-induced (**A**), IL-1 $\beta$ -induced (**B**), and TNF- $\alpha$ -induced (**C**) CXCL8 promoter activation at 24 hours. Values are presented as means  $\pm$  SEMs ( $n = 4$  experiments). \* $P < .05$  and \*\*\* $P < .001$ , 1-way ANOVA with the Bonferroni multiple comparison test. *ns*, Not significant.

**FIG E3.** SOCS1 overexpression inhibited IFN- $\beta$ -induced IFN- $\beta$  and IFN- $\lambda 1$  promoter activation and activation of minimal promoters containing ISRE and STAT1/2 binding sites. Human BECs were transfected with plasmids encoding SOCS1 or empty vector pORF. **A** and **B**, IFN- $\beta$  (5 ng/mL) induced IFN- $\beta$  promoter activation (Fig E3, **A**) and IFN- $\lambda 1$  promoter activation (Fig E3, **B**) at 24 hours, which were both significantly suppressed by SOCS1 ( $n = 4$  experiments). BEAS-2B cells were transfected with plasmids encoding SOCS1 or empty vector pORF. SOCS1 also inhibited both IFN- $\beta$  (5 ng/mL)-induced IFN- $\beta$  promoter activation (Fig E3, **C**) and IFN- $\lambda 1$  promoter activation (Fig E3, **D**) at 24 hours. **E** and **F**, SOCS1 also inhibited IFN- $\beta$ -induced ISRE-driven promoter activation (Fig E3, **E**) and STAT1/2-driven promoter activation (Fig E3, **F**) at 24 hours. Values are presented as means  $\pm$  SEMs ( $n = 3$  experiments). \* $P < .05$ , \*\* $P < .01$ , and \*\*\* $P < .001$ , as indicated, by using 1-way ANOVA with the Bonferroni multiple comparison test.



**FIG E5.** IL-13 treatment increased lung SOCS1 expression. *IFN- $\gamma$* <sup>-/-</sup> C57Bl/6 mice were treated with 0.5  $\mu\text{g}$  of IL-13 or PBS (vehicle) through the intranasal (*i.n.*) route. **A**, Schematic diagram showing the timing of IL-13/PBS treatment and RV1B/UV-RV1B infection 8 hours later. BAL and lung mRNA was harvested at 8, 24, and 48 hours after infection. **B**, IL-13 treatment induced SOCS1 mRNA in *IFN- $\gamma$* <sup>-/-</sup> mice at 4 hours after IL-13 treatment compared with PBS-treated mice. Values are presented as means  $\pm$  SEMs (n = 4 animals per group). \*\* $P < .01$ , *t* test.



**FIG E6.** Mutation of the SOCS1 NLS resulted in reduced suppression of rhinovirus-induced interferon promoter and IFN- $\beta$ -induced minimal ISRE responsive promoter activation with SOCS1wt. **A**, All SOCS1 mutants expressed equally as assessed by anti-GFP detection when compared with anti- $\alpha$ -tubulin using Western blotting (WB). UT, Untransfected. **B**, The SOCS1 NLS mutant  $\Delta$ 6RA showed predominately cytoplasmic localization by using confocal microscopy. Left panel, GFP; right panel, 4'-6-Diamidino-2-phenylindole dihydrochloride. Evans blue and GFP overlay; bar = 10- $\mu$ m scale. A diagram of SOCS1wt and the NLS mutant  $\Delta$ 6RA shows the 6 mutated amino acid residues in the NLS region. **C**,  $\Delta$ 6RA showed less suppression compared with SOCS1wt of RV1B-induced IFN- $\lambda$ 1. **D**, RV1B-induced IFN- $\beta$  promoter activation. **E**, IFN- $\beta$  (5 ng/mL) induced ISRE minimal promoter activation at 24 hours (n = 4 independent experiments). \* $P$  < .05, \*\* $P$  < .01, and \*\*\* $P$  < .001, as indicated and versus RV1B-infected or IFN- $\beta$ -treated GFP-transfected cells. +++ $P$  < .001 versus SOCS1wt-transfected, RV1B-infected, or IFN- $\beta$ -treated cells by using 1-way ANOVA with the Bonferroni multiple comparison test. ns, Not significant (upper ns vs SOCS1wt, RV1B-infected, or IFN- $\beta$ -treated cells; lower ns vs GFP, RV1B-infected, or IFN- $\beta$ -treated cells).

**TABLE E1.** Clinical characteristics of NANA healthy control adults and adults with mild-to-moderate AA used for bronchial biopsies

| Clinical characteristics           | NANA subjects | Patients with AA | P value |
|------------------------------------|---------------|------------------|---------|
| No.                                | 14            | 17               | NA      |
| Sex                                | 43% M/57% F   | 76% M/24% F      |         |
| Age (y)                            | 40 (24-55)    | 34 (21-51)       | .6196   |
| ACQ score                          | 0             | 0.6 (0-3)        | NA      |
| ICS (% of patients)                | 0             | 71               | NA      |
| ICS and LABA (% of patients)       | 0             | 53               | NA      |
| Exacerbations/year                 | 0             | 1 (1-4)          | NA      |
| Oral steroid courses/year (n)      | 0             | 0 (0-1)          | NA      |
| PEF (% predicted)                  | 99 (85-123)   | 91 (66-123)      | .1901   |
| FEV <sub>1</sub> (% predicted)     | 95 (80-107)   | 89 (56-133)      | .4625   |
| FEV <sub>1</sub> /FVC ratio (%)    | 88 (78-95)    | 76 (67-91)       | .0002   |
| PC <sub>20</sub> histamine (mg/mL) | ≥16 (NA)      | 1 (0-4)          | .0002   |
| Total serum IgE (U/mL)             | 9.5 (2-64)    | 127.0 (23-970)   | <.0001  |
| SPT (no. of positive responses)    | 0 (0-0)       | 4 (1-6)          | NA      |

Values are presented as medians (ranges), except for sex, ICS, and ICS plus LABA. Statistical differences were calculated by using the Mann-Whitney *U* test.

ACQ, Asthma control questionnaire; F, female; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting  $\beta_2$ -agonists; M, male; NA, not applicable; PEF, peak expiratory flow; SPT, skin prick test.

**TABLE E2.** Clinical characteristics of NANA control children and atopic children with STRA used for cultured BECs

| Clinical characteristics        | NANA subjects | Children with STRA | P value |
|---------------------------------|---------------|--------------------|---------|
| No.                             | 11            | 11                 |         |
| Sex                             | 64% M/36% F   | 55% M/45% F        | 1.00    |
| Age (y)                         | 7 (2-15)      | 11 (9-15)          | .11     |
| Family history of atopy         | No            | Yes                | NA      |
| Total serum IgE (U/mL)          | NA            | 374 (121-4610)     | NA      |
| No. of positive RAST results    | NA            | 3 (0-6)            | NA      |
| Cumulative RAST score           | NA            | 60.4 (0.03-195)    | NA      |
| Family history of asthma        | No            | Yes                | NA      |
| Physician's diagnosis of asthma | No            | Yes                | NA      |
| FEV <sub>1</sub> (% predicted)  | NA            | 79 (36-108)        | NA      |
| FVC (% predicted)               | NA            | 80.6 (19-111)      | NA      |

Values are presented as medians (ranges), except for sex. RASTs include house dust mite, mixed grass pollen, dog, cat, egg white, peanut, mixed tree pollen, *Aspergillus fumigatus*, *Alternaria* species, *Cladosporium herbarum*, and cockroach. The Mann-Whitney *U* test was used to determine significant differences between the 2 groups. The cumulative RAST score is defined as the total sum of positive RAST scores for each allergen. One hundred percent of children with STRA reported a family history of atopy and asthma and had a physician's diagnosis of asthma. These data were previously reported by Edwards et al.<sup>E6</sup>

F, Female; FVC, forced vital capacity; M, male; NA, not applicable.

**TABLE E3.** TaqMan real-time RT-PCR primers and probes used for quantitative PCR

| Name  | Sequence (5'-3')               |
|---|--------------------------------|
| hIFN- $\beta$ forward (300 nmol/L)                              | cgccgcattgaccatcta             |
| hIFN- $\beta$ reverse (900 nmol/L)                              | ttagccaggaggttctcaacaatagtgtca |
| hIFN- $\beta$ probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])           | tcagacaacattcatctagcactggctgga |
| hIFN- $\lambda$ 1/IL-29 forward (300 nmol/L)                    | ggacgccttgaagagtca             |
| hIFN- $\lambda$ 1/IL-29 reverse (900 nmol/L)                    | agaagcctcaggtccaatc            |
| hIFN- $\lambda$ 1/IL-29 probe<br>(FAM 5'-TAMRA 3' [100 nmol/L]) | agttgcagctctctgtcttccccg       |
| hIFN- $\lambda$ 2/3/IL-28AB forward (300 nmol/L)                | ctgccacatagcccagttca           |
| hIFN- $\lambda$ 2/3/IL-28AB reverse (900 nmol/L)                | agaagcgcacttcttaaggcatctt      |
| hIFN- $\lambda$ 2/3 probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])     | tctccacaggagctgcagccttta       |
| hSOCS1 forward (900 nmol/L)                                     | ccctggtgtgttagcagctt           |
| hSOCS1 reverse (900 nmol/L)                                     | ggtttgtgcaagatactgggtatat      |
| hSOCS1 probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])                  | aggtaggaggtgcgagttcagctctg     |
| hSOCS3 forward (900 nmol/L)                                     | tggacgatagcaaccacaa            |
| hSOCS3 reverse (900 nmol/L)                                     | cgaagtgtcccctgtttgga           |
| hSOCS3 probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])                  | tggattctcctcaattctcagcttccc    |
| mSOCS1 forward (900 nmol/L)                                     | ccgtgggtcgcgagaac              |
| mSOCS1 reverse (900 nmol/L)                                     | aaggaactcaggtagtcacggagta      |
| mSOCS1 probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])                  | tggcgcgcatccctttaacc           |
| mIFN- $\beta$ forward (900 nmol/L)                              | ctccacgctgcgttctgctgtg         |
| mIFN- $\beta$ reverse (900 nmol/L)                              | aaaggattgccacattgtctc          |
| mIFN- $\beta$ probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])           | tcaagcagcctcttctcgat           |
| mTNF- $\alpha$ forward (900M)                                   | agcctgtagcccacgtcgta           |
| mTNF- $\alpha$ reverse (900M)                                   | ttgagatccatgccgttgg            |
| mTNF- $\alpha$ probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])          | aaccaccaagtgaggagcagctgg       |
| 18S forward (300 nmol/L)  | cgccgctagagtgaaattct           |
| 18S reverse (300 nmol/L)  | cattcttgcaaatgcttctg           |
| 18S probe<br>(FAM 5'-TAMRA 3' [100 nmol/L])                     | accggcgcaagacggaccaga          |

*h*, Human; *m*, mouse.